Caixin Global – Latest China News & Headlines

Home >

Beijing’s New Airport Invites Fierce Competition for Seoul and Paris Routes
China Welcomes International Institutions to Take Part in Belt and Road
Fosun Chairman Tells Jack Ma He’s Been ‘Thinking About Succession’
Baidu and ByteDance Launch Tit-for-Tat Lawsuit War
Services Giant Meituan Unveils Multi-Company Ride-Hailing Fleet — But Leaves Didi Out
Star Student Suspected of Killing Mother and Hiding Body for Months Finally Arrested
Leading Chinese Pig Provider Expands Business in Vietnam
Lawsuit Filer Says CEO Offered Her a Job at E-Commerce Giant Before Alleged Rape
Alibaba, Pinduoduo Wash Up on U.S. Piracy List
Payment Firm Lakala Cheers Investors With Surge in Shenzhen Debut
Chinese Sports Info Platform Prepares to Go Public, Again
Biotech Firm Viva to Raise Up to HK$1.5 Billion in Hong Kong IPO
At Least Three Electric Vehicles Have Spontaneously Exploded in China This Week
Fallen Tech Star LeEco's Listed Arm Braces for Trading Suspension
Central Bank Dismisses Rumors, Says It Will Not Tighten or Loosen Monetary Policy
Yet Another Chinese Coffee Chain Joins the Fundraising Frenzy
Former EV Head Is Being Detained — But No One Knows Where or by Whom
China's Bytedance Gets Reprieve as Indian Court Lifts Ban on TikTok App
Pork Company That Once Offered to Pay Debt With Ham Gets Stock-Market Warning
Huawei Opens Cloud and AI Innovation Lab
Guangdong Public Hospital Probed in Deaths of Newborns
China Welcomes International Institutions to Take Part in Belt and Road
Former Guizhou Governor Gets 20 Years in Prison and $26 Million in Fines for Corruption

Fran Wang / Feb 06, 2019 06:47 PM / Business & Tech

Photo: VCG

Photo: VCG

EdiGene Inc., a Beijing-based company developing genome-editing technologies into therapeutics for genetic diseases and cancer, announced it has completed a new round of fund-raising worth $10 million.

The company’s series pre-B plus financing was led by venture capital firm Green Pine Capital Partners, which invests in biotech, new materials, new resources, artificial intelligence and other areas, EdiGene said in a statement earlier this week.

“Our portfolio is entering into an exciting stage, and this new round of financing further validates and continues to support our strategy of translating proprietary platforms into potential therapeutics to patients in need,” said EdiGene CEO Wei Dong.

IDG Capital and Lilly Asia Ventures, which led investment in EdiGene’s series A and series B financing, respectively, are among other investors in this round, according to the statement.

EdiGene was founded in 2015 and currently has subsidiaries in southern China’s Guangzhou and Cambridge in the U.S.

Genome editing has been in the spotlight since late last year, when Chinese scientist He Jiankui said a team he led had removed genes from two fetuses in an attempt to make them HIV-resistant. He said the resulting children were born in November. This led to international condemnation, with the government ordering inspections of gene-editing work at universities nationwide and He himself disappearing from public view.

Related: ‘Pursuit of Fame’ Drove Controversial Gene-Editing Project, Investigation Says

Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.